<DOC>
	<DOCNO>NCT00088660</DOCNO>
	<brief_summary>The objective multi-center , randomize , control trial evaluate safety efficacy PANVAC-VF combination Granulocyte-macrophage colony-stimulating factor ( GM-CSF ) versus best supportive care palliative chemotherapy .</brief_summary>
	<brief_title>PANVACâ„¢-VF Vaccine Treatment Metastatic Pancreatic Cancer After Failing Gemcitabine-Containing Regimen</brief_title>
	<detailed_description>PANVAC-VF investigational cancer vaccine . The vaccine base theory body taught fight cancer direct immune system attack specific target find cancer cell . These target call Tumor Associated Antigens , TAA 's . This trial help determine vaccine help fight cancer . All patient require sign inform consent prior performance study-related procedure . Patients screen eligibility within 14 day prior anticipate treatment start date ( Day 0 ) . Patients meet inclusion exclusion criterion centrally randomize study receive unique patient identification number treatment assignment . The ratio active treatment control 1:1 ( PANVAC-VF : best supportive care palliative chemotherapy ) .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patients &gt; 18 year age vaccinate smallpox ; Histologically confirm diagnosis adenocarcinoma pancreas ; Patient metastatic ( Stage IV ) disease ; ECOG performance status 01 ; Failed gemcitabinecontaining chemotherapeutic regimen within 3 month study entry . Prior concurrent immunotherapy cancer ; Radiation therapy within 28 day prior registration ; Systemic corticosteroid therapy ( except inhale topical steroid ) within 28 day registration ; Significant cardiovascular abnormality diseases ; Known positive HIV , hepatitis B and/or C ; Evidence immunodeficiency immune suppression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>Metastatic</keyword>
</DOC>